Instead, he sees the money trickling back into his pocket as he covers the usual post-graduate expenses of rent and graduate school, among daily costs.
"When I was an undergrad, the last thing I thought about was saving money," the Northeastern University graduate student says. "I knew after graduation that I wanted to make money but still wasn't concerned with conserving it."
Frias' financial woes are not uncommon among Generation Yers��hose born in the early 80s to early 2000s��ut a recent study shows broke Millennials may not be deserving of the infamous reputations they've earned when it comes to financial decisions.
A recent Pew Research Center study indicates that while student debt is greater than before, Millennials are shedding more debt than their predecessors, Generation X.
Top Forestry Companies To Own For 2015: AMR Corp (AAMRQ)
AMR Corporation (AMR), incorporated in October 1982, operates in the airline industry. The Company�� principal subsidiary is American Airlines, Inc. (American). As of December 31, 2011, American provided scheduled jet service to approximately 160 destinations throughout North America, the Caribbean, Latin America, Europe and Asia. AMR Eagle Holding Corporation (AMR Eagle), a wholly owned subsidiary of AMR, owns two regional airlines, which do business as American Eagle - American Eagle Airlines, Inc. and Executive Airlines, Inc. (collectively, the American Eagle carriers). American also contracts with an independently owned regional airline, which does business as AmericanConnection (the AmericanConnection carrier). As of December 31, 2011, AMR Eagle operated approximately 1,500 daily departures, offering scheduled passenger service to over 175 destinations in North America, Mexico and the Caribbean.
American, AMR Eagle and the AmericanConnection airline served more than 250 cities in approximately 50 countries with, on average, 3,400 daily flights and the combined network fleet numbered approximately 900 aircraft as of December 31, 2011. American Airlines is also a founding member of the oneworld alliance, which includes British Airways, Cathay Pacific, Finnair, LAN Airlines, Iberia, Qantas, JAL, Malev Hungarian, Mexicana, Royal Jordanian and S7 Airlines. Together, oneworld members serve 750 destinations in approximately 150 countries, with about 8,500 daily departures. American is also one of the scheduled air freight carriers in the world, providing a range of freight and mail services to shippers throughout its system onboard American�� passenger fleet.
To improve access to each other�� markets, American has established marketing relationships with other airlines and rail companies. As of December 31, 2011, American had marketing relationships with Air Berlin, Air Pacific, Air Tahiti Nui, Alaska Airlines, British Airways, Cape Air, Cathay Pacific, China Eastern Airl! ines, Dragonair, Deutsche Bahn German Rail, EL AL, Etihad Airways, EVA Air, Finnair, GOL, Gulf Air, Hawaiian Airlines, Iberia, Japan Airlines (JAL), Jet Airways, JetStar Airways, LAN (includes LAN Airlines, LAN Argentina, LAN Ecuador and LAN Peru), Niki Airlines, Qantas Airways, Royal Jordanian, S7 Airlines, and Vietnam Airlines.
American has established the AAdvantage frequent flyer program (AAdvantage). AAdvantage members earn mileage credits by flying on American, American Eagle and the AmericanConnection carrier or by using services of other participants in the AAdvantage program. Mileage credits can be redeemed for free, discounted or upgraded travel on American, American Eagle or other participating airlines, or for other awards. American sells mileage credits and related services to other participants in the AAdvantage program. There are over 1,000 program participants, including a credit card issuer, hotels, car rental companies, and other products and services companies in the AAdvantage program. As of December 31, 2011, AAdvantage had approximately 69 million total members.
The Company competes with Alaska Airlines (Alaska), Delta Air Lines (Delta), Frontier Airlines, JetBlue Airways (JetBlue), Hawaiian Airlines, Southwest Airlines (Southwest) and AirTran Airways (Air Tran), Spirit Airlines, United Airlines (United) and Continental Airlines (Continental), US Airways and Virgin America Airlines.
Advisors' Opinion:- [By Alexander MacLennan]
Experimental method
On certain routes, American Airlines, a subsidiary of AMR (NASDAQOTH: AAMRQ ) , is testing a new selling method of allowing passengers to bid on upgrades. In its own words, American Airlines explains how the process works. - [By Ben Levisohn]
Shares of United Continental have dropped 0.6% to $31.11 today at 11:33 a.m., while Delta has gained 1.2% to $26.63, US Airways has risen 1.8% to $23.07 and AMR Corp. (AAMRQ) has risen 1.7% to $7.02.
Top Up And Coming Companies To Watch For 2014: Atossa Genetics Inc (ATOS)
Atossa Genetics Inc., incorporated on April 30, 2009, is a development-stage healthcare company focused on the prevention of breast cancer through the commercialization of diagnostic tests that can detect precursors to breast cancer, and through the research, development, and ultimate commercialization of treatments for pre-cancerous lesions. The Company�� diagnostic tests consist of medical devices cleared by the Food and Drug Administration (FDA), which can collect fluid samples from the breast milk ducts, where over 95% of breast cancers arise. During the fiscal year ended September 30, 2012, the tests that the Company offered and that are in development consist of ForeCYTE, ArgusCYTE, FullCYTE and NextCYTE. In September 2012, the Company acquired all of the assets of Acueity.
The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 73. The ArgusCYTE Breast Health Test provides information to help inform breast cancer treatment options and to help monitor potential recurrence. The FullCYTE Breast Health Test is designed to assess the individual breast ducts for pre-cancerous changes in women previously identified to be at high risk for breast cancer. The NextCYTE Breast Cancer Test is designed to profile breast cancer specimens for prediction of treatment outcomes and distant recurrence in women newly diagnosed with breast cancer. MASCT, Oxy-MASCT, and its name and logo are the trademarks. ForeCYTE, FullCYTE, NextCYTE, and ArgusCYTE are its service marks.
Advisors' Opinion:- [By Rebecca McClay]
Atossa Genetics Inc. (Nasdaq: ATOS) shares are up about 6% in midday trading due to a cancer breakthrough it plans to showcase this weekend...
Atossa will exhibit its ForeCYTE Breast Health Test at the 2013 Breast Cancer Symposium in San Francisco, CA, which starts Saturday.
- [By Roberto Pedone]
One stock that's starting to push within range of triggering a big breakout trade is Apple (ATOS), which is involved in the prevention of breast cancer through the commercialization of diagnostic medical devices and laboratory developed tests that can detect precursors to breast cancer. This stock is off to a decent start in 2013, with shares up 24%.
If you take a look at the chart for Atossa Genetics, you'll notice that this stock has been starting to uptrend over the last month, with shares moving higher from its low of $4.22 to its recent high of $5.08 a share. During that uptrend, shares of ATOS have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of ATOS within range of triggering a big breakout trade above a key downtrend line that dates back to May.
Traders should now look for long-biased trades in ATOS if it manages to break out above some key overhead resistance levels at $5.08 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average volume of 74,575 shares. If that breakout hits soon, then ATOS will set up to re-test or possibly take out its next major overhead resistance levels at $5.60 to $6.23 a share. Any high-volume move above $6.23 will then put $7 to $7.50 into range for shares of ATOS.
Traders can look to buy ATOS off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $4.42 or at $4.22 a share. One could also buy ATOS off strength once it takes out $5.08 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By Bryan Murphy]
You know, it's fun to be right about a particular stock, but at the same time, it's miserable if you didn't have the guts to actually act on the idea. That's my tale of woe with Atossa Genetics Inc. (NASDAQ:ATOS). On Monday of this week I was singing its praises, explaining how the chart suggested ATOS was on the verge of a breakout. But, I also suggested waiting for shares to take that one final confirming step.... a move above the 100-day moving average line. Now I wish I hadn't been so picky.
Top Up And Coming Companies To Watch For 2014: Insmed Inc.(INSM)
Insmed Incorporated, a biopharmaceutical company, focuses on the development of inhaled pharmaceuticals for the site-specific treatment of serious lung diseases. The company primarily focuses on the development of inhaled antibiotic therapy delivered via proprietary advanced pulmonary liposome technology in areas of high unmet need in lung diseases. Its lead product candidate includes ARIKACE, an inhaled antibiotic supported by positive phase 2 results for treating serious lung infections due to susceptible bacteria. The U.S. Food and Drug Administration has cleared the company's investigational new drug application to conduct a pivotal Phase 3 clinical trial of ARIKACE in nontuberculous mycobacteria lung infections. Insmed Incorporated was founded in 1999 and is based in Monmouth Junction, New Jersey.
Advisors' Opinion:- [By Brian Pacampara]
What: Shares of biotechnology company Insmed (NASDAQ: INSM ) plunged 15% today after a phase 3 trial of the company's experimental lung-infection drug Arikace disappointed Wall Street. �
- [By Eric Volkman]
Insmed (NASDAQ: INSM ) will have nearly $60 million at its disposal if a new public stock offering goes as planned. The company is floating 6 million shares of its common stock in a public issue that has been priced at $10.40 per share. The gross take will be $62.4 million, which the firm said should net it around $58 million after fees and expenses.
- [By Sean Williams]
The bad
Don't say I didn't tell you so, but Insmed (NASDAQ: INSM ) shares sank like a stone after reporting late-stage results for Arikace, its experimental treatment for non-tuberculosis mycobacterial lung infections. Although Arikace met its primary endpoint of being non-inferior to the current standard of treatment, TOBI, which is made by Novartis, the results didn't exactly wow analysts who now see limited upside even if it's approved by the FDA. Simply put, without any measurable differentiation, Insmed could have a hard time gaining sales traction and is still quite the long shot to be profitable. - [By Jake L'Ecuyer]
Leading and Lagging Sectors
Monday morning, the healthcare sector proved to be a source of strength for the market. Leading the sector was strength from Nordion (NYSE: NDZ) and Insmed (NASDAQ: INSM).
Top Up And Coming Companies To Watch For 2014: Furiex Pharmaceuticals Inc (FURX)
Furiex Pharmaceuticals, Inc. is a drug development collaboration company. The Company�� product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas. Its programs include Priligy, Alogliptin Nesina, Alogliptin/Actose Combination, Alogliptin/Metformin Combination, Fluoroquinolone, Mu Delta and PPD 10558. In November 2011, it acquired full exclusive license rights to develop and commercialize the compound MuDelta under its existing development and license agreement with Janssen Pharmaceutica N.V.
Priligy (dapoxetine) is a drug developed for the on-demand treatment of premature ejaculation (PE). Dapoxetine is a short-acting, selective serotonin reuptake inhibitor (SSRI) designed to be taken only when needed one to three hours before sexual intercourse is anticipated rather than every day. Nesina (alogliptin) is a drug for the oral treatment of type 2 diabetes (T2D). Alogliptin is a DPP-4 inhibitor that slows the inactivation of incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP).
Fluoroquinolone drug candidate is a Phase II-ready novel fluoroquinolone antibiotic that is being developed by the Company for the treatment of complicated skin and skin structure infections, such as abscesses that occur deep in the skin layers and respiratory infections. This antibiotic has a spectrum of activity and is able to treat methicillin-resistant staphylococcus aureus (MRSA) infections. The Company is developing both oral and intravenous (IV) formulations. The Company is developing Mu Delta for treatment of diarrheal predominant irritable bowel syndrome (d-IBS). The Company is conducting a Phase II study on an oral formulation of Mu Delta.
The Company is developing PPD 10558 for the treatment of dyslipidemia. PPD 10558 has shown muscle safety in preclinical studies by minimizing the delivery of the drug to the muscle. The Company has filed an inve! stigational new drug (IND) application with the United States Food and Drug Association and completed five clinical studies.
Advisors' Opinion:- [By Lisa Levin]
Furiex Pharmaceuticals (NASDAQ: FURX) shares moved up 28.41% to $102.92. The volume of Furiex Pharmaceuticals shares traded was 2285% higher than normal. Forest Labs (NYSE: FRX) announced its plans to buy Furiex Pharma for up to $1.46 billion.
- [By Lauren Pollock var popups = dojo.query(".socialByline .popC"); popups.forEach]
Forest Laboratories Inc.(FRX) agreed to acquire Furiex Pharmaceuticals(FURX) in a deal worth up to $1.33 billion that expands Forest Labs’ presence in gastroenterology. Furiex surged 28% to $102.21 premarket.
- [By Jake L'Ecuyer]
Top Headline
Forest Laboratories (NYSE: FRX) announced its plans to buy Furiex Pharmaceuticals (NASDAQ: FURX) for up to $1.46 billion. Forest will pay around $95 per share, or around $1.1 billion in cash. Forest Labs will also pay up to $30 per share, or around $360 million in a contingent value right. The deal is projected to close in the second or third quarter of 2014.
Top Up And Coming Companies To Watch For 2014: Reynolds American Inc(RAI)
Reynolds American Inc. (RAI), through its subsidiaries, manufactures and sells cigarette and other tobacco products in the United States. It offers cigarettes under the brand names of CAMEL, PALL MALL, WINSTON, KOOL, DORAL, SALEM, MISTY, and CAPRI; and cigarettes and other tobacco products under the NATURAL AMERICAN SPIRIT brand name, as well as manages various licensed brands, including DUNHILL and STATE EXPRESS 555. The company also provides smokeless tobacco products, including moist snuff under GRIZZLY and KODIAK brand names; pasteurized tobacco under CAMEL Snus brand name; milled tobacco under the brand name of CAMEL Dissolvables; other tobacco products, such as little cigars under WINCHESTER and CAPTAIN BLACK brand names; and roll-your-own tobacco under the brand name of BUGLER. RAI sells its products primarily through distributors, wholesalers, and other direct customers, including retail chains, as well as distributes its cigarettes to public warehouses. The compan y was founded in 1875 and is headquartered in Winston-Salem, North Carolina.
Advisors' Opinion:- [By Ben Levisohn]
Tiffany surged 9.2% to $62.63 after raising its earnings guidance, while Netflix climbed 5.1% to $390.60 after announcing that it would expand into six European countries. Lorillard spiked 10% to $62.63 on reports that it’s in talks to be purchased by Reynolds American (RAI). Reynolds American gained 4.4% to $59.77.
Top Up And Coming Companies To Watch For 2014: Halozyme Therapeutics Inc.(HALO)
Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of recombinant human enzymes that transiently modify tissue under the skin to facilitate injection of other therapies or correct diseased tissue structures for clinical benefits. The company primarily offers recombinant human hyaluronidase, an enzyme that degrades hyaluronan, which is a matrix component in the skin, and facilitates the dispersion and absorption of drugs and fluids. Its portfolio of products and product candidates are developed based principally on intellectual property covering the family of human enzymes known as hyaluronidases. The company also provides Ultrafast Insulin program, a Phase II clinical trial product for the treatment of diabetes mellitus; and Enhanze technology, a proprietary drug delivery platform for subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as sma ll molecules and fluids. It offers PEGPH20, a new molecular entity that is in Phase I trial for the systemic treatment of tumors; and HTI-501, a recombinant human proteinase, which is in Phase 1/2 clinical trial used for the treatment of edematous fibrosclerotic panniculopathy (cellulite). The company has collaborative partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.; ViroPharma Incorporated; and Intrexon Corporation to apply Enhanze technology to the partners? biological therapeutic compounds. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Advisors' Opinion:- [By Maxx Chatsko]
The treatment will add to its quickly growing expertise in blood treatments and biologics. Speaking of which, Baxter and Halozyme (NASDAQ: HALO ) had HyQvia approved for marketing in Europe�earlier this year. The therapy boosts the immune systems of patients with primary and secondary immunodeficiencies, and combines multiple therapies -- both intravenous and subcutaneous -- into one subcutaneous product. It also allows patients to administer treatment at home every three to four weeks. In other words, it knocks the convenience category out of the park. Halozyme has had a tumultuous life on the public market, so this could be just the stabilizer shareholders need.
- [By Sean Williams]
The EMA's Committee for Medicinal Products for Human Use, or CHMP, also played a big role in Halozyme Therapeutics' (NASDAQ: HALO ) huge Friday surge. The EMA's panel recommended Roche's Herceptin SC, which uses Halozyme's recombinant human hyaluronidase in a subcutaneous injection for patients with HER2-positive breast cancer. A typical infusion of Herceptin can take 30 to 90 minutes, whereas the subcutaneous injection can be delivered in a fraction of the time, two to five minutes. This new delivery method could save hospitalization time and money and improve patient comfort. It could also be a transformative approval for Halozyme.�
- [By Keith Speights]
Halozyme Therapeutics (NASDAQ: HALO ) isn't quite as close to commercialization. The company has a mid-stage study under way that combines its rHuPH20 hyaluronidase enzyme with a mealtime insulin analog. Halozyme's enzyme helps the insulin to be absorbed more quickly than it would normally.
Top Up And Coming Companies To Watch For 2014: Amarok Energy Inc (AMR)
Amarok Energy Inc.(Amarok ), formerly Drako Capital Corp. (Drako) is Canada-based company, engaged in oil and natural gas exploration and development in North America and Colombia. The Company operates in Canada, United States and Colombia. On February 27, 2012, Drako announced the completion of the Qualifying Transaction. On August 22, 2012, Drako Capital Corp. acquired Trilateral Energy Ltd. As part of the business acquisition of Trilateral a net carried working interest of 5% in Block LLA-21 for the two oil wells to be drilled on the Block LLA-21 property was acquired. As part of the business acquisition of Trilateral, oil and gas lease rights located in Montana, USA were acquired. 6,204 net acres (6,949 gross acres) of leases have been secured and approximately seven miles of two-dimensional (2D) seismic was acquired. Advisors' Opinion:- [By Holly LaFon]
Question (From Bill Miller of Legg Mason): The airline industry is plagued with terrible economics. With the pending merger with U.S. Air (LCC) and American (AMR)��the industry has been consistently profitable with double-digit returns. Do you think the industry�� improved economics are likely to improve?
- [By Dimitra DeFotis]
A more temporary phenomenon beset airline stocks, with passenger revenue affected internationally by World Cup soccer mania. Leading the airline stocks lower were United Continental Holdings�(UAL),�Delta Air Lines (DAL) and American Airlines (AMR).
No comments:
Post a Comment